Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review
Immune checkpoint inhibitors cause rare but potentially fatal neuromuscular complications, leading to a concern to use these agents in cancer patients with pre-existing autoimmune or inflammatory neuromuscular diseases. We report two such patients with paraneoplastic dermatomyositis and “seronegativ...
Main Authors: | Ge Xiong, Richard Benjamin Young, Helen Chow, Emanual Maverakis, Ricardo A. Maselli, David Paul Richman, Tianhong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1199195/full |
Similar Items
-
Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
by: Elena E. Perez, et al.
Published: (2021-07-01) -
Relationship between Body Composition and Serum Immunoglobulin Concentrations after Administration of Intravenous Immune Globulin–Preclinical and Clinical Evidence
by: Luigi Brunetti, et al.
Published: (2023-02-01) -
Neutropaenia following intravenous immunoglobulin therapy in paediatric patients with immune thrombocytopaenia
by: Martyna Szuster, et al.
Published: (2024-06-01) -
Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
by: Stephan von Gunten, et al.
Published: (2023-03-01) -
Therapeutic Immunoglobulin Selected For High Antibody Titer to RSV Also Contains High Antibody Titers to Other Respiratory Viruses
by: Jordan eOrange
Published: (2015-08-01)